Clinical TrialsNEXICART-2 trial clinical sites footprint expanded, facilitating acceleration of enrollment and advancing Immix's path to Biologics License Application submission for FDA approval.
Market OpportunityThere are currently no FDA-approved agents available for treatment of relapsed/refractory AL amyloidosis, highlighting the potential market opportunity for NXC-201.
Trial ResultsInterim NEXICART-2 trial data appeared encouraging, with a 100% response rate and a 70% hematologic complete response rate without observed relapses or progression.